Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.66 |
| ▸ | CTSD | P07339 | 14/20 | 0.66 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342901 | 0.94 | BACE1 (0.67) | BACE1CTSDBACE2 | |
| SCHEMBL6346674 | 0.92 | BACE1 (0.65) | BACE1CTSDBACE2 | |
| SCHEMBL6340340 | 0.92 | BACE1 (0.56) | BACE1CTSDBACE2 | |
| SCHEMBL6077474 | 0.92 | BACE1 (0.62) | BACE1CTSDBACE2 | |
| SCHEMBL6345210 | 0.91 | BACE1 (0.55) | BACE1CTSDBACE2 | |
| SCHEMBL6355011 | 0.91 | BACE1 (0.63) | BACE1CTSDBACE2 | |
| SCHEMBL6343440 | 0.91 | BACE1 (0.63) | BACE1CTSDBACE2 | |
| SCHEMBL6077182 | 0.90 | BACE1 (0.61) | BACE1CTSDBACE2 | |
| SCHEMBL6342388 | 0.90 | BACE1 (0.62) | BACE1CTSDBACE2 | |
| SCHEMBL6341821 | 0.90 | BACE1 (0.62) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906104-B2 | Aminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-14 | — | — | US | claimed |
| US-20030092747-A1 | Aminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2003-05-15 | — | — | US | claimed |
| US-6906104-B2 | Aminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1395251-A2 | AMINEDIOLS AS AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20030092747-A1 | Aminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2003-05-15 | — | — | US | disclosed |
| WO-2002100818-A2 | AMINEDIOLS AS AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092747-A1 | Aminediols for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | BACE1 1/4885CTSD 213/4885BACE2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.